Dragonfly Therapeutics Inc. CEO Bill Haney told BioWorld that his firm's deal with Merck & Co. Inc. provides "a pretty considerable up-front payment" and gives Merck the option to license exclusive worldwide intellectual property rights to products developed using the TriNKET natural killer (NK) cell technology platform against solid tumors for an undisclosed number of programs.